Background: Globally, 1 in 11 adults have diabetes mellitus and 90% of the cases are type 2 diabetes mellitus. Insulin resistance is a central defect in type 2 diabetes mellitus, and although multiple drugs have been developed to ameliorate insulin resistance, the limitations and accompanying side effects cannot be ignored. Thus more effective methods are required to improve insulin resistance.
Methods: In the current study, db/m and db/dbmice were injected with human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) via tail vein injection, intraperitoneal injection and skeletal muscle injection. Body weight, fasting blood glucose and the survival rates were monitored. Furthermore, the anti-insulin resistance effects and potential mechanisms of transplanted HUC-MSCs were investigated in db/db mice in vivo.
Results: The results showed that HUC-MSC transplantation by skeletal muscle injection was safer compared with tail vein injection and intraperitoneal injection, and the survival rate reached 100% in the skeletal muscle injection transplanted mice. HUC-MSCs can stabilize localization and differentiation in skeletal muscle tissue and significantly ameliorate insulin resistance. Potential regulatory mechanisms are associated with downregulation of inflammation; regulating the balance between PI3K/Akt and ERK/MAPK signaling pathway via PTEN, but was not associated with the IGF-1/IGF-1R signaling pathway.
Conclusions: These results suggest HUC-MSC transplantation may be a novel therapeutic direction to prevent insulin resistance and increase insulin sensitivity, and skeletal muscle injection was the safest and most effective way.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...
Posted 30 Jul, 2020
On 16 Sep, 2020
On 24 Jul, 2020
On 24 Jul, 2020
On 23 Jul, 2020
On 23 Jul, 2020
On 14 Jul, 2020
Received 19 Jun, 2020
Received 10 Jun, 2020
Received 10 Jun, 2020
On 06 Jun, 2020
Invitations sent on 04 Jun, 2020
On 04 Jun, 2020
On 04 Jun, 2020
On 26 May, 2020
On 25 May, 2020
On 25 May, 2020
On 18 May, 2020
Received 15 May, 2020
Received 15 May, 2020
Received 13 May, 2020
On 07 May, 2020
On 07 May, 2020
On 05 May, 2020
Invitations sent on 28 Apr, 2020
On 28 Apr, 2020
On 20 Apr, 2020
On 19 Apr, 2020
On 19 Apr, 2020
On 03 Apr, 2020
Received 09 Mar, 2020
On 09 Mar, 2020
On 09 Mar, 2020
Received 09 Mar, 2020
Invitations sent on 05 Mar, 2020
On 24 Feb, 2020
On 23 Feb, 2020
On 21 Feb, 2020
On 18 Feb, 2020
Posted 30 Jul, 2020
On 16 Sep, 2020
On 24 Jul, 2020
On 24 Jul, 2020
On 23 Jul, 2020
On 23 Jul, 2020
On 14 Jul, 2020
Received 19 Jun, 2020
Received 10 Jun, 2020
Received 10 Jun, 2020
On 06 Jun, 2020
Invitations sent on 04 Jun, 2020
On 04 Jun, 2020
On 04 Jun, 2020
On 26 May, 2020
On 25 May, 2020
On 25 May, 2020
On 18 May, 2020
Received 15 May, 2020
Received 15 May, 2020
Received 13 May, 2020
On 07 May, 2020
On 07 May, 2020
On 05 May, 2020
Invitations sent on 28 Apr, 2020
On 28 Apr, 2020
On 20 Apr, 2020
On 19 Apr, 2020
On 19 Apr, 2020
On 03 Apr, 2020
Received 09 Mar, 2020
On 09 Mar, 2020
On 09 Mar, 2020
Received 09 Mar, 2020
Invitations sent on 05 Mar, 2020
On 24 Feb, 2020
On 23 Feb, 2020
On 21 Feb, 2020
On 18 Feb, 2020
Background: Globally, 1 in 11 adults have diabetes mellitus and 90% of the cases are type 2 diabetes mellitus. Insulin resistance is a central defect in type 2 diabetes mellitus, and although multiple drugs have been developed to ameliorate insulin resistance, the limitations and accompanying side effects cannot be ignored. Thus more effective methods are required to improve insulin resistance.
Methods: In the current study, db/m and db/dbmice were injected with human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) via tail vein injection, intraperitoneal injection and skeletal muscle injection. Body weight, fasting blood glucose and the survival rates were monitored. Furthermore, the anti-insulin resistance effects and potential mechanisms of transplanted HUC-MSCs were investigated in db/db mice in vivo.
Results: The results showed that HUC-MSC transplantation by skeletal muscle injection was safer compared with tail vein injection and intraperitoneal injection, and the survival rate reached 100% in the skeletal muscle injection transplanted mice. HUC-MSCs can stabilize localization and differentiation in skeletal muscle tissue and significantly ameliorate insulin resistance. Potential regulatory mechanisms are associated with downregulation of inflammation; regulating the balance between PI3K/Akt and ERK/MAPK signaling pathway via PTEN, but was not associated with the IGF-1/IGF-1R signaling pathway.
Conclusions: These results suggest HUC-MSC transplantation may be a novel therapeutic direction to prevent insulin resistance and increase insulin sensitivity, and skeletal muscle injection was the safest and most effective way.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...